HYML-122 + cytarabine

**HYML-122 + cytarabine** is a combination therapy under clinical investigation for the treatment of FLT3-positive relapsed or refractory acute myeloid leukemia (AML). HYML-122 is a potent, orally available small molecule inhibitor of FLT3 (FMS-like tyrosine kinase 3), a receptor tyrosine kinase frequently mutated in AML, developed by Hefei Institutes of Physical Science in collaboration with Hefei Cosource Pharmaceuticals and Tarapeutics Science. Cytarabine is a well-established antimetabolite chemotherapeutic agent primarily used in AML therapy. The combination targets FLT3-driven leukemic cell proliferation and DNA synthesis, combining targeted and cytotoxic mechanisms. Clinical studies are ongoing in China, focused on efficacy and safety in the relapsed/refractory FLT3-mutant AML setting[1][5].

Other names

HYML 122 + cytarabine